BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Catalym GmbH

Headquarters: Munich, Germany
Year Founded: 2016
Status: Private

BioCentury | Oct 23, 2024
Management Tracks

Shaun Grady to chair AstraZeneca UK

Plus: Phil L’Huillier named CEO of Scancell, and updates from BioPorto and Parexel
BioCentury | Jul 18, 2024
Finance

Venture Report: Five biotechs raise nearly $800M in two-day flurry 

Plus: New capital for CytoReason, Truvian and Renalys
BioCentury | Dec 7, 2023
Politics, Policy & Law

Dec. 6 Quick Takes: Pfizer CEO excoriates university presidents on antisemitism failure

Plus: J&J’s Duato: GLP-1 space ‘too crowded’ to enter, Pfizer leaving BIO and updates from Merck KGaA, Pharvaris, Novartis, Arvinas, Seagen, EyePoint and CatalYm
BioCentury | Dec 14, 2022
Finance

Brandon Capital goes to Europe

Australian VC tapping European innovation while hoping to attract top-tier VCs to domestic opportunities
BioCentury | Nov 22, 2022
Finance

Nov. 22 Quick Takes: Brandon, Jeito lead €50M round for CatalYm

Plus Arvinas falls on protein degradation data and updates from Turbine, GSK, argenx and more
BioCentury | May 5, 2021
Management Tracks

Shearman named Editas CSO; plus Kyowa Kirin, Excision, IDbyDNA, and more

Mark Shearman will join Editas Medicine Inc. (NASDAQ:EDIT) in June as EVP and CSO. Shearman currently serves as CSO of Applied Genetic Technologies Corp. (NASDAQ:AGTC). Kyowa Kirin Co. Ltd.
BioCentury | Mar 4, 2021
Management Tracks

Amazon exec Lathia joins Flagship-backed Valo as chief product officer; plus AavantiBio, CatalYm, Corcept, Vincerx, OnCusp and more

Flagship-backed cloud computing-based drug discovery and development company Valo Health LLC named Nish Lathia chief product officer. The 18-year veteran of Amazon.com Inc. (NASDAQ:AMZN) held a
BioCentury | Nov 11, 2020
Emerging Company Profile

CatalYm: opening up tumors to immune cells

Emerging Company Profile: German start-up targets GDF15’s immunosuppressant function to enable immune cell infiltration to tumors
BioCentury | Nov 3, 2017
Financial News

BioGeneration closes Ventures Fund III at EUR82M

BioCentury | Oct 31, 2017
Financial News

BioGeneration closes third fund

Items per page:
1 - 10 of 12
Help Center
Username
Request a Demo
Request Training
Ask a Question